Dermatomyositis: 2026 so far

Trial evidence matured, with benefit paired to infection risk.

In the months covered, a phase 3 placebo-controlled trial (a late-stage study comparing a treatment to an inactive pill) reported that brepocitinib 30 mg improved overall disease activity at 52 weeks versus placebo in adults whose dermatomyositis was resistant to prior therapy. Improvements were seen as early as week 4. Later reporting focused on skin results. A randomized trial analysis showed better skin activity, less itch, and better skin-related quality of life versus placebo through week 52. In the same phase 3 trial, serious infections were reported more often with brepocitinib 30 mg than placebo (10% vs 1%). No deaths occurred in the trial. This gives more solid evidence for symptom improvement, while also making the infection-safety tradeoff more concrete for treatment conversations.

Research covered in: March 2026, August 2026

More pathway-targeted skin and itch reports appeared in 2026.

In January-September reports, several targeted medicines were linked to improvement in difficult skin symptoms, including itch. Most of the evidence was small or did not compare against another treatment. In the skin-predominant group of a phase 2 randomized, double-blind, placebo-controlled trial (a mid-stage trial testing whether a treatment works and is safe), dazukibart showed early improvements in skin activity and itching versus placebo, with benefits maintained through week 12. Later follow-up reported continued skin improvement through week 76 in an open-label extension (a follow-on study where everyone knows the treatment being given). Side effects were mostly mild or moderate, and no treatment-related serious side effects were reported. Small real-world reports described itch and skin score improvement with nemolizumab (5-person retrospective series) and near-complete skin improvement with anifrolumab in two patients, along with a drop in a type I interferon blood signature (a lab pattern linked to immune activation). These reports widen the list of investigational or off-label approaches being tried for skin and itch, but they still leave open questions about how long benefits last, how they compare to other options, and how safety looks in larger groups.

Research covered in: May 2026, June 2026, August 2026

More JAK-inhibitor lung reports, with benefits and infection concerns.

So far in 2026, observational and real-world reports added information on JAK inhibitors (a type of immune-targeting medicine) for anti-MDA5 dermatomyositis with interstitial lung disease (ILD) (scarring or inflammation in the lungs). Results were mixed, and infection risk was highlighted repeatedly. A multicenter observational comparison reported upadacitinib was non-inferior to tofacitinib for 6-month lung-transplant-free survival, with similar reported safety profiles. A separate 40-person retrospective cohort linked upadacitinib to improvements in overall activity, skin, strength testing, and ILD measures. It also noted common infections and anti-MDA5 worsening/relapse in some patients. Case-based reports described improvement with add-on upadacitinib in severe anti-MDA5 ILD, including a 3-person series using intensive combination therapy where serious opportunistic infections occurred in one patient. Overall, these reports show JAK-inhibitor approaches are being used in high-risk lung disease, but the balance between possible benefit and infection risk remains uncertain outside non-randomized studies.

Research covered in: February 2026, April 2026, August 2026, September 2026

More CT-and-blood risk tools emerged; rapid ILD prediction stayed limited.

In the months covered, multiple cohorts and meta-analyses added practical risk signals for anti-MDA5-associated ILD using CT severity and patterns, plus routine blood markers. Examples included lymphocyte counts, neutrophil-to-lymphocyte ratio, ferritin, LDH, and CRP. Some studies also built nomograms (risk calculators that combine several factors) using these features. Several reports emphasized that rapidly progressive ILD (lung disease that worsens quickly) and complications like spontaneous pneumomediastinum (air leaking into the chest space) were linked to high short-term mortality in anti-MDA5-positive groups. In a single-center study of 162 people with idiopathic inflammatory myopathies, not specifically anti-MDA5 dermatomyositis, KL-6 plus lung ultrasound B-lines performed very well overall for identifying ILD, but performance appeared weaker in an exploratory subgroup with rapidly progressive ILD. Small hospitalized cohorts also showed substantial overlap in inflammatory markers between survivors and non-survivors. This points to more data-driven risk estimation overall, while still leaving no single score or lab test that can reliably predict an individual course when lung disease is rapidly worsening.

Research covered in: January 2026, February 2026, April 2026, May 2026, June 2026, July 2026, August 2026, September 2026

Risk models and audits highlighted clustering and screening gaps.

In the January-September reports, multiple cohorts reinforced that cancer-associated dermatomyositis/myositis tended to cluster near disease onset. It was repeatedly linked to older age and anti-TIF1-gamma positivity. Studies also reported that many patients did not receive the full set of guideline-recommended screening tests in real-world practice. Screening patterns varied by region, which complicates interpretation of observed cancer rates. Several case reports in the months covered described dermatomyositis symptoms improving after cancer-directed therapy, but these single-patient experiences cannot estimate how often this happens or predict outcomes. Together, this supports why clinicians often discuss risk-based cancer evaluation around the time dermatomyositis begins, while also showing that screening is not carried out consistently in practice.

Research covered in: February 2026, May 2026, July 2026, August 2026, September 2026